

## Involvement of endogenous tachykinins in LTD<sub>4</sub>-induced airway responses

J. Ishikawa, M. Ichinose, M. Miura, N. Kageyama,  
H. Yamauchi, M. Tomaki, Y. Sasaki, K. Shirato

*Involvement of endogenous tachykinins in LTD<sub>4</sub>-induced airway responses. J. Ishikawa, M. Ichinose, M. Miura, N. Kageyama, H. Yamauchi, M. Tomaki, Y. Sasaki, K. Shirato. ©ERS Journals Ltd 1996.*

**ABSTRACT:** Leukotriene D<sub>4</sub> (LTD<sub>4</sub>) has been reported to cause tachykinin release from airway sensory nerves. However, the functional significance of endogenously released tachykinins in LTD<sub>4</sub>-mediated airway responses has not been fully clarified.

The aim of this study was to investigate whether LTD<sub>4</sub>-induced airway responses are due, in part, to tachykinin release in guinea-pigs. Airway plasma exudation and bronchoconstriction were assessed by measuring extravasation of Evans blue dye and by mean pulmonary resistance (RL) in the presence of atropine (1 mg·kg<sup>-1</sup> *i.v.*) and propranolol (1 mg·kg<sup>-1</sup> *i.v.*), respectively.

LTD<sub>4</sub> (5 µg·mL<sup>-1</sup> for 1 min) inhalation caused increase in plasma exudation and RL. Capsaicin pretreatment of animals to deplete sensory neuropeptides significantly inhibited LTD<sub>4</sub>-induced plasma exudation in the main bronchi, but not in the central (cIPA) and peripheral intrapulmonary airways (pIPA). Pretreatment with specific tachykinin neurokinin-1 (NK<sub>1</sub>)-receptor antagonists, FK 888 (10 mg·kg<sup>-1</sup> *i.v.*) and CP 96345 (4 mg·kg<sup>-1</sup> *i.v.*), also significantly reduced LTD<sub>4</sub>-induced plasma exudation in the main bronchi, and in the main bronchi and cIPA, respectively. However, these antagonists did not significantly affect the LTD<sub>4</sub>-induced increase in RL. In contrast, neurokinin-2 (NK<sub>2</sub>)-receptor antagonist, SR 48968 (0.3 mg·kg<sup>-1</sup> *i.v.*), significantly inhibited the bronchoconstriction after LTD<sub>4</sub>-inhalation.

These results suggest that leukotriene D<sub>4</sub>-induced bronchoconstriction and plasma exudation in guinea-pigs are, in part, due to tachykinin release from airway sensory nerves.

*Eur Respir J., 1996, 9, 486–492.*

First Department of Internal Medicine,  
Tohoku University School of Medicine,  
Sendai, Japan.

Correspondence: K. Shirato  
First Department of Internal Medicine  
Tohoku University School of Medicine  
1-1 Seiryō-machi  
Aoba-ku  
Sendai 980  
Japan

Keywords: Asthma  
leukotriene D<sub>4</sub>-receptor  
neurokinin-receptor  
plasma leakage  
sensory neuropeptides

Received: April 25 1995  
Accepted after revision October 25 1995

Airway inflammation is recognized to be important in the pathogenesis of asthma and this phenomenon involves inflammatory cell-derived mediators, neural abnormality, and interactions between these two factors [1]. Among the inflammatory mediators, sulphidopeptide leukotrienes (LTs) are thought to play an important role in the pathogenesis of the disease, because recently developed receptor antagonists or synthesis inhibitors of LTs improve basal pulmonary function [2, 3] and protect antigen- and exercise-induced airway narrowing in asthmatic patients [4, 5]. Neuropeptides, especially tachykinins, released from airway sensory nerves are important, since these peptides cause airway smooth muscle contraction, microvascular leakage, and mucus secretion, which are compatible with the features of asthma [6].

There are several reports concerning the interaction between leukotriene D<sub>4</sub> (LTD<sub>4</sub>) and tachykinins. In guinea-pig ileum, LTD<sub>4</sub> causes substance P (SP) release and the contractile response to LTD<sub>4</sub> is partially inhibited by SP antagonists, indicating that SP has a role in mediating the effect of LTD<sub>4</sub> in the longitudinal smooth muscle of

the ileum [7]. A recent report showed that infusion of LTD<sub>4</sub> *via* the airways resulted in the enhanced recovery of SP- and neurokinin A (NKA)-like immunoreactivities from the lung [8], suggesting that LTD<sub>4</sub> also causes tachykinin release from airway sensory nerves. Further, bronchial smooth muscle contraction and vascular leakage by stimulation of capsaicin-sensitive sensory fibres are partially inhibited by LTD<sub>4</sub>-antagonists, suggesting that tachykinins cause endogenous LT release [9]. However, the functional significance of endogenously released tachykinins in LTD<sub>4</sub>-mediated airway responses has not been fully clarified.

Thus, in this study, using chronic capsaicin administration, which causes tachykinin depletion, and neurokinin (NK)-receptor antagonist pretreatment, it was demonstrated that LTD<sub>4</sub> causes airway responses *via* tachykinin release from airway sensory nerves. The airway inflammation was assessed by Evans blue dye leakage into airway tissues as a marker of microvascular leakage, and the bronchoconstrictor response was quantified by means of pulmonary resistance (RL) measurements.

## Methods

### Animal preparations

Male Dunkin-Hartley guinea-pigs ( $n=70$ ; Funabashi Farm, Funabashi, Japan) weighing 350–450 g were anaesthetized with an intraperitoneal injection of urethane (2 g·kg<sup>-1</sup>). Animals were placed on a heated pad (Deltaphase Isothermal Pad, model 39DP, Braintree Science Inc., UK) to maintain the body temperature at about 37°C. Both external jugular veins were exposed for administration of drugs. All animals were pretreated 30 min before experimentation with atropine and propranolol (1 mg·kg<sup>-1</sup> *i.v.*, for both,) to block muscarinic and  $\beta$ -adrenergic receptor-mediated modification, respectively. The doses of atropine and propranolol were chosen according to previous studies [10, 11]. A tracheal cannula was inserted into the lumen of the cervical trachea, and this cannula was connected to a constant volume mechanical ventilator (Model SN-480-7; Shinano Seisakusho, Tokyo, Japan) at a frequency of 60 strokes·min<sup>-1</sup> and at a tidal volume ( $V_T$ ) of 1 mL·100 g<sup>-1</sup>.

### Pulmonary resistance

Airflow ( $V'$ ) was determined by connecting a pneumotachograph (Model 00; Fleisch, Lausanne, Switzerland) to the tracheal cannula and measuring the pressure drop across the device with a differential pressure transducer (MP45,  $\pm 5$  cmH<sub>2</sub>O; Validyne Corp., Northridge, CA, USA).  $V_T$  was determined by electrical integration of the air-flow signal. Pleural pressure ( $P_{pi}$ ) was measured by means of an oesophageal balloon connected to the differential pressure transducer (MP45,  $\pm 100$  cmH<sub>2</sub>O). Transpulmonary pressure ( $P_{tp}$ ) was obtained by electrical subtraction of  $P_{pi}$  from airway opening pressure ( $P_{ao}$ ). Pulmonary resistance ( $RL$ ) was obtained by a subtraction method [12].  $RL$  change was monitored after LTD<sub>4</sub> inhalation for 5 min.

### Measurement of airway plasma exudation

Vascular permeability was quantified by the extravasation of Evans blue dye, which correlates well with the extravasation of radiolabelled albumin in guinea-pig airways [13]. Evans blue dye (30 mg·kg<sup>-1</sup>, 30 mg in 1 mL saline) which was filtered using a 0.22  $\mu$ m Millipore filter, was injected into the jugular vein 1 min before LTD<sub>4</sub> (5  $\mu$ g·mL<sup>-1</sup> for 1 min) or saline (for 1 min) inhalation. The inhalation challenge was performed using an ultrasonic nebulizer (mean particle size = 5  $\mu$ m; manufacturer's specification) (NE-U11B; Omron, Tateishi Co., Tokyo, Japan) interposed between the inspiratory part of the ventilator and the tracheal cannula. After the induction of leakage (5 min after the LTD<sub>4</sub> challenge), the thorax was opened and a catheter was inserted into the aorta through a left ventriculotomy. Ventricles were cross-clamped, and blood was expelled through an incision in the right atrium at 80 mmHg pressure with about 100 mL saline (pH 5.5) until the perfusate became clear. The lungs were removed, and parenchyma was scraped off.

The main bronchi and the intrapulmonary airways were separated from each other. The intrapulmonary airways were divided into central (cIPA, the proximal 3 mm portion) and peripheral (pIPA, the remaining distal portion) components as described previously [10, 11]. All tissues were blotted dry and weighed. Evans blue dye was extracted in 2 mL of formamide at 37°C incubation for 16 h. Dye concentration was quantified from light absorbance at 620 nm (Spectrophotometer 220A; Hitachi Ltd., Tokyo, Japan) and expressed as ng dye per mg wet weight of tissue, as calculated from a standard curve of dye concentrations in the range of 0.5–10  $\mu$ g·mL<sup>-1</sup>.

### Capsaicin pretreatment

Animals were anaesthetized with ketamine (50 mg·kg<sup>-1</sup> *i.m.*) and xylazine (0.1 mg·kg<sup>-1</sup> *i.m.*). Aminophylline (25 mg·kg<sup>-1</sup> *i.p.*) and terbutaline (0.1 mg·kg<sup>-1</sup> *s.c.*) were given 30 min before capsaicin administration to protect against bronchoconstriction. Capsaicin (50 mg·kg<sup>-1</sup> *s.c.*) or vehicle for capsaicin (ethanol/Tween 80, 1 mL·kg<sup>-1</sup> *s.c.*) was injected, and animals were studied 1 week after treatment.

### Experimental protocols

The effects of intravenously administered neurokinin-1 (NK<sub>1</sub>) antagonist, FK 888, or LTD<sub>4</sub> antagonist, ONO-1078, on LTD<sub>4</sub>-induced Evans blue dye exudation were studied in seven groups: Group I: dimethylsulphoxide (DMSO, vehicle for both antagonists, 0.1 mL·kg<sup>-1</sup>) and saline inhalation ( $n=5$ ); Group II: FK 888 (10 mg·kg<sup>-1</sup>) and saline inhalation ( $n=5$ ); Group III: ONO-1078 (200  $\mu$ g·kg<sup>-1</sup>) and saline inhalation ( $n=5$ ); Group IV: DMSO and LTD<sub>4</sub> inhalation ( $n=6$ ); Group V: FK 888 (1 mg·kg<sup>-1</sup>) and LTD<sub>4</sub> inhalation ( $n=6$ ); Group VI: FK 888 (10 mg·kg<sup>-1</sup>) and LTD<sub>4</sub> inhalation ( $n=7$ ); Group VII: ONO-1078 (200  $\mu$ g·kg<sup>-1</sup>) and LTD<sub>4</sub> inhalation ( $n=5$ ). DMSO, FK 888 or ONO-1078 was administered 1 min before Evans blue dye injection (30 mg·kg<sup>-1</sup> *i.v.*). LTD<sub>4</sub> or saline inhalation followed 1 min after the injection of Evans blue dye.

In a separate set of experiments, the effects of another NK<sub>1</sub>-receptor antagonist, CP 96345 (4 mg·kg<sup>-1</sup> *i.v.*), neurokinin-2 (NK<sub>2</sub>)-receptor antagonist, SR 48968 (0.3 mg·kg<sup>-1</sup> *i.v.*), or vehicle of both antagonists, DMSO (0.1 mL·kg<sup>-1</sup> *i.v.*;  $n=5$ ) on LTD<sub>4</sub>-induced airway responses were studied. The doses of FK 888, CP 96345, and SR 48968 were chosen according to previous studies [14–16].

In a separate experiment, guinea-pigs chronically pretreated with capsaicin ( $n=8$ ) or the vehicle of capsaicin ( $n=8$ ) were challenged with LTD<sub>4</sub> inhalation to examine the effect of tachykinin depletion on the LTD<sub>4</sub>-induced response.

### Drugs and chemicals

FK 888 and ONO-1078 were kindly donated by Fujisawa Pharmaceutical Co. Ltd (Osaka, Japan) and Ono Pharmaceutical Co. Ltd (Osaka, Japan), respectively. CP 96345 was obtained from Yamanouchi Pharmaceutical Co. Ltd. (Ibaraki, Japan) and SR 48968 was kindly donated by X. Emonds-Alt (Sanofi Recherche, France). Evans blue dye was purchased from Aldrich Chemical Co. Inc.

(Milwaukee, WIS, USA). Substance P, urethane and xy-lazine were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Dimethylsulphoxide (DMSO), ethanol, formamide and Tween 80 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). Atropine sulphate was obtained from Tanabe Chemical Co. (Osaka, Japan). Propranolol hydrochloride was purchased from Imperial Chemical Industries plc (Macclesfield, UK). Five percent Glucose and saline (0.9% sodium chloride) were obtained from Otsuka Chemical Co. (Tokyo, Japan). Aminophylline was purchased from Eisai Co. Ltd (Tokyo, Japan). Ketamine was obtained from Sankyo Co. Ltd (Tokyo, Japan).

FK 888 and ONO-1078 were dissolved in 100% DMSO at the concentration of 100 and 2 mg·mL<sup>-1</sup>, respectively, and these antagonists were injected by microsyringe (MS-N50; Terumo, Tokyo, Japan) at a volume of 0.1 mL·kg<sup>-1</sup>. Capsaicin was diluted to a concentration of 50 mg·mL<sup>-1</sup> in 10% ethanol, 10% Tween 80 and 80% saline.

#### Statistical analysis

Data are expressed as mean±SEM. Comparisons of the concentration of extractable Evans blue dye among groups were made with Student's unpaired t-test with Bonferroni correction. The degree of LTD<sub>4</sub>-induced bronchoconstriction was analysed by two-way analysis of variance

between groups, and Student's unpaired t-test. Probability values of less than 0.05 were considered significant.

## Results

#### Effect of ONO-1078 on LTD<sub>4</sub>-induced plasma exudation

The tissue content (mean±SEM) of Evans blue dye in response to saline inhalation challenge (basal plasma exudation) in main bronchi, cIPA and pIPA was 13.8±3.3, 18.9±8.8 and 17.4±4.6 ng·mg<sup>-1</sup> tissue, respectively (fig. 1). LTD<sub>4</sub> inhalation significantly increased Evans blue dye exudation in main bronchi to 127.1±16.2, in cIPA to 124.9±8.4, and in pIPA to 178.3±18.2 ng·mg<sup>-1</sup> tissue. ONO-1078 (200 µg·kg<sup>-1</sup> *i.v.*) itself had no significant effect on the basal plasma exudation in any component of the airways, but almost completely inhibited the LTD<sub>4</sub>-induced plasma exudation in all airways (fig. 1).

#### Effect of FK 888 on LTD<sub>4</sub>-induced plasma exudation

FK 888 (10 mg·kg<sup>-1</sup> *i.v.*) itself also had no significant effect on basal extravasation in any part of the airways (fig. 2). LTD<sub>4</sub> inhalation-induced plasma exudation was significantly reduced by intravenous injection of FK 888 at the dose of 10 mg·kg<sup>-1</sup> in main bronchi but not in intrapulmonary airways (fig. 2).




Fig. 1. – Histogram illustrating the degree of Evans blue dye exudation evoked by LTD<sub>4</sub> (5 µg·mL<sup>-1</sup> in saline for 1 min) inhalation challenge in guinea-pig airways. □: response to saline inhalation challenge (for 1 min) after *i.v.* injection of DMSO (vehicle for ONO-1078, 0.1 mL·kg<sup>-1</sup>, n=5). ▨: response to saline inhalation after ONO-1078 (200 µg·kg<sup>-1</sup>, *i.v.*, n=5). ▩: response to LTD<sub>4</sub> inhalation after *i.v.* injection of DMSO (n=6). ▧: response to LTD<sub>4</sub> inhalation after ONO-1078. Values are presented as mean±SEM. cIPA and pIPA: central and peripheral intrapulmonary airways, respectively; LTD<sub>4</sub>: leukotriene D<sub>4</sub>; DMSO: dimethylsulphoxide; ONO: ONO-1078. ††: p<0.01, compared with values of saline inhalation after DMSO administration; \*\*: p<0.01, compared with the value of LTD<sub>4</sub> inhalation after DMSO administration.




Fig. 2. – Effects of NK<sub>1</sub> receptor antagonist, FK 888 (FK), on LTD<sub>4</sub>-induced airway plasma exudation in main bronchi, and central (cIPA) and peripheral intrapulmonary airways (pIPA). □: response to saline inhalation (for 1 min) after *i.v.* injection of DMSO (vehicle for FK 888, 0.1 mL·kg<sup>-1</sup>, n=5). ▨: response to saline inhalation after FK 888 (10 mg·kg<sup>-1</sup>, *i.v.*, n=5). ▩: response to LTD<sub>4</sub> inhalation (5 µg·mL<sup>-1</sup>, for 1 min) after *i.v.* injection of DMSO (n=6). ▧: response to LTD<sub>4</sub> inhalation after FK 888 (1 mg·kg<sup>-1</sup>, *i.v.*, n=6; and 10 mg·kg<sup>-1</sup>, *i.v.*, n=7). Values are presented as mean±SEM. ††: p<0.01, compared with values of saline inhalation after intravenous injection of DMSO. \*\*: p<0.01, compared with the values of LTD<sub>4</sub> inhalation after intravenous injection of DMSO. FK1: FK 888 0.1 mg·kg<sup>-1</sup>; FK10: FK 888 10 mg·kg<sup>-1</sup>. For further abbreviations see legend to figure 1.




Fig. 3. – Effect of CP 96345 (CP) and SR 48968 (SR) on LTD<sub>4</sub>-induced airway plasma exudation. Values are presented as mean±SEM. : response to LTD<sub>4</sub> inhalation (5 µg·mL<sup>-1</sup>, for 1 min) after *i.v.* injection of DMSO (n=5); : response to LTD<sub>4</sub> inhalation after CP 96345 (4 mg·kg<sup>-1</sup> *i.v.*, n=5); : response to LTD<sub>4</sub> inhalation after SR 48968 (0.3 mg·kg<sup>-1</sup> *i.v.*, n=5). \*: p<0.05; and \*\*: p<0.01, compared with the values of DMSO (vehicle for CP and SR, n=5) pretreatment. For abbreviations see legend to figure 1.




Fig. 4. – Effect of capsaicin pretreatment on LTD<sub>4</sub>-induced airway plasma exudation in guinea-pig airways. : response to LTD<sub>4</sub> inhalation (5 µg·mL<sup>-1</sup>, for 1 min) after pretreatment with vehicle for capsaicin (vehicle, n=8). : response to LTD<sub>4</sub> inhalation after pretreatment with capsaicin (50 mg·kg<sup>-1</sup> *i.m.*, n=8). Values are presented as mean±SEM. \*\*: p<0.01, compared with the value of vehicle pretreatment. For abbreviations see legend to figure 1.

#### Effect of CP 96345 and SR 48968 on LTD<sub>4</sub>-induced plasma exudation

CP 96345 (4 mg·kg<sup>-1</sup> *i.v.*) significantly inhibited LTD<sub>4</sub>-induced airway plasma exudation in main bronchi and cIPA, but not in pIPA (fig. 3). SR 48968 (0.3 mg·kg<sup>-1</sup> *i.v.*) did not have a significant effect on LTD<sub>4</sub>-mediated plasma exudation in any airways (fig. 3).

#### Effect of the capsaicin pretreatment on LTD<sub>4</sub>-induced plasma exudation

In the vehicle for capsaicin pretreated animals, LTD<sub>4</sub> inhalation-caused Evans blue dye exudation in main bronchi, cIPA and pIPA of 140.0±20.5, 133.5±12.1 and 197.3±23.0 ng·mg<sup>-1</sup> tissue, respectively. This exudation was significantly reduced by capsaicin pretreatment in main bronchi but not in intrapulmonary airways (fig. 4).

#### Effect of ONO-1078 and FK 888 on the LTD<sub>4</sub>-induced changes in pulmonary resistance

LTD<sub>4</sub> inhalation challenge significantly increased RL at 1–5 min after the challenge (fig. 5). ONO-1078 (200 µg·kg<sup>-1</sup> *i.v.*) significantly inhibited RL changes evoked by LTD<sub>4</sub> challenge. On the other hand, FK 888 (10 mg·kg<sup>-1</sup> *i.v.*) did not significantly affect the LTD<sub>4</sub>-induced RL changes (fig. 5).




Fig. 5. – Effect of FK 888 and ONO-1078 on pulmonary resistance (RL) changes evoked by LTD<sub>4</sub> inhalation (5 µg·mL<sup>-1</sup>, for 1 min) challenge in guinea-pig airways. The shaded area indicates the period of LTD<sub>4</sub> inhalation. —○— : response to LTD<sub>4</sub> inhalation after intravenous injection of DMSO (vehicle for ONO-1078 and FK 888) (n=6); —●— : response to LTD<sub>4</sub> inhalation after FK 888 (10 mg·kg<sup>-1</sup> *i.v.*, n=7); —■— : response to LTD<sub>4</sub> inhalation after ONO-1078 (200 µg·kg<sup>-1</sup> *i.v.*, n=5). Values are presented as mean±SEM. †: p<0.05; and ††: p<0.01, compared with the values of preinhalation (pre); \*: p<0.05; and \*\*: p<0.01, compared with the values of LTD<sub>4</sub> inhalation after intravenous injection of DMSO. RL: pulmonary resistance. For further abbreviations see legend to figure 1.




Fig. 6. – Effect of CP 96345 (●) and SR 48968 (■) on pulmonary resistance (RL) changes evoked by LTD<sub>4</sub> inhalation. The shaded area indicates the period of LTD<sub>4</sub> inhalation (for 1 min). ○ : response to LTD<sub>4</sub> inhalation after DMSO pretreatment (n=5). Values are presented as mean±SEM. All points after LTD<sub>4</sub> inhalation were significantly different from the preinhalation (pre) values (p<0.05). At 1 and 2 min after LTD<sub>4</sub> inhalation, RL values of SR 48968 pretreatment were significantly lower than those of DMSO pretreatment (p<0.05). There was no significant difference between the values of CP 96345 and DMSO pretreatment. RL: pulmonary resistance. For further abbreviations see legend to figure 1.

#### Effect of CP 96345 and SR 48968 on the LTD<sub>4</sub>-induced changes in pulmonary resistance

SR 48968 (0.3 mg·kg<sup>-1</sup> *i.v.*) pretreatment significantly inhibited the LTD<sub>4</sub>-induced RL increase at 1 and 2 min after the inhalation (fig. 6). In contrast, CP 96345 (4 mg·kg<sup>-1</sup> *i.v.*) had no significant effect on the LTD<sub>4</sub>-mediated RL increase (fig. 6).

### Discussion

In the present study, it was shown that LTD<sub>4</sub> inhalation causes microvascular leakage from central to peripheral airways. The LTD<sub>4</sub> (and LTC<sub>4</sub>) receptor antagonist ONO-1078 almost completely blocked the LTD<sub>4</sub>-induced airway microvascular leakage, indicating that this response is LT receptor specific. In guinea-pigs, airway microvascular leakage by LTD<sub>4</sub> has been demonstrated using Evans blue dye [17, 18] and <sup>125</sup>I-bovine serum albumin [19] as a tracer for plasma exudation, and the results were compatible with our data.

To investigate the possible involvement of endogenously released tachykinins in LTD<sub>4</sub>-induced airway microvascular leakage, two different kinds of strategies were employed, *i.e.* capsaicin or NK<sub>1</sub>-receptor antagonist pretreatment. Capsaicin has selective effects on peptide-containing C-fibres [20–22], and systemic administration of this compound may result in temporary or permanent depletion of neuropeptides from these nerves - a process known as capsaicin desensitization [23]. Capsaicin-pretreated animals fail to develop neurogenic airway microvascular leakage upon sensory nerve stimulation [21, 24–26]. On the other hand, SP is about eight times more potent than neurokinin A or B (NKA or NKB), suggesting that NK<sub>1</sub> receptors are most important for the

tachykinin-mediated airway microvascular leakage in guinea-pigs [27]. NK<sub>1</sub> receptors have been localized to postcapillary venules which are the leaky sites [28, 29]. Further, the NK<sub>1</sub>-receptor antagonist, FK 888, has been reported to abolish sensory nerve stimulation [30] or exogenous SP [31]-mediated responses. In the present study, both pretreatments (capsaicin desensitization and NK<sub>1</sub>-receptor antagonist pretreatment) significantly inhibited LTD<sub>4</sub>-induced airway microvascular leakage in central airways, suggesting that, in this portion, the LTD<sub>4</sub>-mediated airway microvascular leakage is, in part, mediated *via* tachykinin release from sensory nerves.

Administration of LTD<sub>4</sub> into the airways has been shown to enhance the recovery of SP- and NKA-like immunoreactivities from the lung, suggesting that LTD<sub>4</sub> causes the tachykinin release from airway sensory nerves [8]. However, conflicting results have been reported on the role played by tachykinins in the LTD<sub>4</sub>-mediated responses in different tissues. In guinea-pig ileum, the LTD<sub>4</sub>-mediated contractile response is partially inhibited by a neurotoxin, tetrodotoxin. This inhibitory effect is abolished by capsaicin desensitization or pretreatment with an SP antagonist, indicating that SP is released from neurones by LTD<sub>4</sub> in guinea-pig ileum [7]. In contrast, MANZINI and MEINI [32] have reported that capsaicin desensitization does not affect the bronchial contraction elicited by LTD<sub>4</sub> in guinea-pigs. The results of our present investigation are compatible with the former study.

In the present study, both capsaicin desensitization and NK<sub>1</sub>-receptor antagonist pretreatment inhibited the LTD<sub>4</sub>-induced airway microvascular leakage in central but not in peripheral airways, suggesting that tachykinin-mediated mechanisms are involved in LTD<sub>4</sub>-induced inflammation in central rather than peripheral airways. SP-immunoreactive nerves are distributed in all airways [33], but sensory nerve-stimulation-induced airway microvascular leakage is more predominant in central and mid-airways than in distal airways [34, 35]. Taken together, LTD<sub>4</sub> inhalation may cause airway sensory nerve stimulation and result in the release of endogenous SP mainly in the central airways. Thus, in central airways, the LTD<sub>4</sub>-induced airway microvascular leakage is due to the activation both of NK<sub>1</sub>- and LTD<sub>4</sub>-receptors on the endothelium of airway postcapillary venules. In contrast, in peripheral airways, LTD<sub>4</sub>-mediated response may be due to LTD<sub>4</sub>- but not NK<sub>1</sub>-receptors. A similar effect of endogenous tachykinins in central airways after bradykinin administration into the airways has also been reported [14].

In the present study, we observed significant inhibitory effects of FK 888 only in the high dose range compared with the former studies [30, 31]. Therefore, the nonspecific effect of this antagonist may influence our results. However, another NK<sub>1</sub>-receptor antagonist, CP 96345, also showed a similar inhibitory effect on LTD<sub>4</sub>-induced responses. Thus, we believe that the effect of FK 888 observed in this study was a NK<sub>1</sub>-receptor specific response.

In the present study, LTD<sub>4</sub> inhalation caused significant bronchoconstriction. In contrast to the plasma leakage, NK<sub>1</sub>-receptor antagonists, FK 888 or CP 96345, did

not affect the bronchoconstrictor response elicited by LTD<sub>4</sub> administration. However, NK<sub>2</sub>-receptor antagonist, SR 48968, significantly inhibited the LTD<sub>4</sub>-induced RL elevation. These results are in keeping with observations in humans *in vivo*, showing a slight increase in maximal bronchoconstriction to LTD<sub>4</sub> following pretreatment with an inhibitor (thiorphan) or tachykinin-degrading enzyme, neutral endopeptidase [36]. Because tachykinins have been reported to cause airway smooth muscle contraction *via* NK<sub>2</sub>-receptors [6, 27], the LTD<sub>4</sub>-induced RL elevation observed in the present study seems to be due to the airway smooth muscle contraction rather than airway plasma leakage and subsequent airway wall oedema.

In summary, we have shown that LTD<sub>4</sub> inhalation causes airway microvascular extravasation and bronchoconstriction. Both chronic capsaicin administration, which causes tachykinin depletion, and NK<sub>1</sub>-receptor antagonist pretreatment partially but significantly reduced the plasma exudation in central airways. Furthermore, NK<sub>2</sub>-receptor antagonist significantly inhibited the LTD<sub>4</sub>-induced bronchoconstrictor response. These results suggest that the LTD<sub>4</sub>-induced airway responses are, in part, mediated *via* tachykinin release from airway sensory nerves.

**Acknowledgement:** The authors thank B. Bell for reading the manuscript.

#### References

- McFadden ER Jr, Gilbert IA. Asthma. *N Engl J Med* 1992; 327: 1928–1937.
- Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. *Lancet* 1991; 337: 1062–1063.
- Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D<sub>4</sub> (LTD<sub>4</sub>) receptor antagonist (MK-571) in patients with asthma. *Am Rev Respir Dis* 1992; 146: 358–362.
- Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. *Lancet* 1991; 337: 690–694.
- Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D<sub>4</sub>-receptor antagonist. *N Engl J Med* 1990; 323: 1736–1739.
- Barnes PJ, Baraniuk JN, Belvisi MG. Neuropeptides in the respiratory tract. Part I. *Am Rev Respir Dis* 1991; 144: 1187–1198.
- Bloomquist EI, Kream RM. Leukotriene D<sub>4</sub> acts in part to contract guinea-pig ileum smooth muscle by releasing substance P. *J Pharmacol Exp Ther* 1987; 240: 523–528.
- Martins MA, Shore SA, Drazen JM. Release of tachykinins by histamine, methacholine, PAF, LTD<sub>4</sub>, and substance P from guinea-pig lungs. *Am J Physiol* 1991; 261 (Lung Cell Mol Physiol 5): L449–L455.
- Ellis JL, Udem BJ. Role of peptidoleukotrienes in capsaicin-sensitive sensory fibre-mediated responses in guinea-pig airways. *J Physiol (Lond)* 1991; 436: 469–484.
- Ichinose M, Miura M, Takahashi T, *et al.* Antigen-induced airway responses are inhibited by a potassium channel opener. *Am J Respir Crit Care Med* 1994; 150: 388–393.
- Ishikawa J, Ichinose M, Nakajima N, *et al.* Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea-pig airways. *Am J Respir Crit Care Med* 1994; 150: 1379–1383.
- Mead J, Whittenberger JL. Physical properties of human lungs measured during spontaneous respiration. *J Appl Physiol* 1953; 5: 779–796.
- Rogers DF, Boschetto P, Barnes PJ. Plasma exudation: correlation between Evans blue dye and radiolabelled albumin in guinea-pig airways *in vivo*. *J Pharmacol Methods* 1989; 21: 309–315.
- Nakajima N, Ichinose M, Takahashi T, *et al.* Bradykinin-induced airway inflammation: contribution of sensory neuropeptides differs according to airway site. *Am J Respir Crit Care Med* 1994; 149: 694–698.
- Bertrand C, Geppetti P, Baker J, Yamawaki I, Nadel JA. Role of neurogenic inflammation in antigen-induced vascular extravasation in guinea-pig trachea. *J Immunol* 1993; 150: 1479–1485.
- Qian Y, Emonds-Alt X, Advenier C. Effects of capsaicin, (±)-CP-96345 and SR 48968 on the bradykinin-induced airways microvascular leakage in guinea-pigs. *Pulm Pharmacol* 1993; 6: 63–67.
- Hua X-Y, Dahlen S-E, Lundberg JM, Hammarstrom S, Hedqvist P. Leukotrienes C<sub>4</sub>, D<sub>4</sub> and E<sub>4</sub> cause widespread and extensive plasma extravasation in the guinea-pig. *Naunyn Sch Arch Pharmacol* 1985; 330: 136–141.
- Obata T, Kobayashi T, Okada Y, Nakagawa N, Terawaki T, Aishita H. Effect of a peptide leukotriene antagonist, ONO-1078 on antigen-induced airway microvascular leakage in actively sensitized guinea-pigs. *Life Sci* 1992; 51: 1577–1583.
- Woodward DF, Weichman BM, Gill CA, Wasserman MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. *Prostaglandins* 1983; 25: 131–142.
- Jancso N, Jancso-Gabor A, Szolcanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. *Br J Pharmacol* 1967; 31: 138–151.
- Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. *Neuroscience* 1988; 24: 739–768.
- Saria A, Martling C-R, Yan Z, Theodorsson-Norheim E, Gamse R, Lundberg JM. Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. *Am Rev Respir Dis* 1988; 137: 1330–1335.
- Jancso N. Desensitization with capsaicin and related acylamides as a tool for studying the function of pain receptors. *In: Lim RSK, ed. Pharmacology of Pain.* Oxford, Pergamon Press, 1968; pp. 33–55.
- Nagy JI, Iversen LL, Goedert M, Chapman D, Hunt SP. Dose-dependent effects of capsaicin on primary sensory neurons in the neonatal rat. *J Neurosci* 1983; 3: 399–406.
- Jancso G, Kiraly E, Joo F, Such G, Nagy A. Selective degeneration by capsaicin of a subpopulation of primary sensory neurons in the adult rat. *Neurosci Lett* 1985; 59: 209–214.
- Ichinose M, Barnes PJ. A potassium channel activator

- modulates both excitatory noncholinergic and cholinergic neurotransmission in guinea-pig airways. *J Pharmacol Exp Ther* 1990; 252: 1207–1212.
27. Solway J, Leff AR. Sensory neuropeptides and airway function. *J Appl Physiol* 1991; 71: 2077–2087.
  28. Persson CGA. Role of plasma exudation in asthmatic airways. *Lancet* 1986; 2: 1126–1129.
  29. McDonald DM. Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. *Am J Physiol* 1994; 266 (Lung Cell Mol Physiol 10): L61–L83.
  30. Hirayama Y, Lei Y-H, Barnes PJ, Rogers DF. Effects of two novel tachykinin receptor antagonists, FK 224 and FK 888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea-pig *in vivo*. *Br J Pharmacol* 1993; 108: 844–851.
  31. Fujii T, Murai M, Morimoto H, *et al.* Pharmacological profile of a high affinity dipeptide NK<sub>1</sub> receptor antagonist, FK 888. *Br J Pharmacol* 1992; 107: 785–789.
  32. Manzini S, Meini S. Involvement of capsaicin-sensitive nerves in the bronchomotor effects of arachidonic acid and melittin: a possible role for lipoxin A<sub>4</sub>. *Br J Pharmacol* 1991; 103: 1027–1032.
  33. Lundberg JM, Hokfelt T, Martling CR, Saria A, Cuello C. Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man. *Cell Tissue Res* 1984; 235: 251–261.
  34. Belvisi MG, Rogers DF, Barnes PJ. Neurogenic plasma extravasation: inhibition by morphine in guinea-pig airways *in vivo*. *J Appl Physiol* 1989; 66: 268–272.
  35. Ichinose M, Belvisi MG, Barnes PJ. Histamine H<sub>3</sub>-receptors inhibit neurogenic microvascular leakage in airways. *J Appl Physiol* 1990; 68: 21–25.
  36. Diamant Z, Timmers MC, van de Veen H, Booms P, Sont JK, Sterk PJ. Effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responsiveness to leukotriene D<sub>4</sub> in normal and asthmatic subjects. *Eur Respir J* 1994; 7: 459–466.